Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berzosertib + Radiation Therapy in Breast Cancer
NCT04052555Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2020
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of berzosertib in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Recommended Phase 2 Dose at 4 weeks. Started Sep 2020; status: active, not recruiting.
02
Drugs
berzosertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04052555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04052555.